TY - JOUR
T1 - AIM2 inflammasome mediates hallmark neuropathological alterations and cognitive impairment in a mouse model of vascular dementia
AU - Poh, Luting
AU - Fann, David Y.
AU - Wong, Peiyan
AU - Lim, Hong Meng
AU - Foo, Sok Lin
AU - Kang, Sung Wook
AU - Rajeev, Vismitha
AU - Selvaraji, Sharmelee
AU - Iyer, Vinaya Rajagopal
AU - Parathy, Nageiswari
AU - Khan, Mohammad Badruzzaman
AU - Hess, David C.
AU - Jo, Dong Gyu
AU - Drummond, Grant R.
AU - Sobey, Christopher G.
AU - Lai, Mitchell K.P.
AU - Chen, Christopher Li Hsian
AU - Lim, Lina H.K.
AU - Arumugam, Thiruma V.
N1 - Funding Information:
Funding This work was supported by the National Medical Research Council Research Grants (NMRC-CBRG-0102/2016 and NMRC/ OFIRG/0036/2017), Singapore and the startup fund to TVA from La Trobe University, Melbourne, Australia.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/8
Y1 - 2021/8
N2 - Chronic cerebral hypoperfusion is associated with vascular dementia (VaD). Cerebral hypoperfusion may initiate complex molecular and cellular inflammatory pathways that contribute to long-term cognitive impairment and memory loss. Here we used a bilateral common carotid artery stenosis (BCAS) mouse model of VaD to investigate its effect on the innate immune response—particularly the inflammasome signaling pathway. Comprehensive analyses revealed that chronic cerebral hypoperfusion induces a complex temporal expression and activation of inflammasome components and their downstream products (IL-1β and IL-18) in different brain regions, and promotes activation of apoptotic and pyroptotic cell death pathways. Polarized glial-cell activation, white-matter lesion formation and hippocampal neuronal loss also occurred in a spatiotemporal manner. Moreover, in AIM2 knockout mice we observed attenuated inflammasome-mediated production of proinflammatory cytokines, apoptosis, and pyroptosis, as well as resistance to chronic microglial activation, myelin breakdown, hippocampal neuronal loss, and behavioral and cognitive deficits following BCAS. Hence, we have demonstrated that activation of the AIM2 inflammasome substantially contributes to the pathophysiology of chronic cerebral hypoperfusion-induced brain injury and may therefore represent a promising therapeutic target for attenuating cognitive impairment in VaD.
AB - Chronic cerebral hypoperfusion is associated with vascular dementia (VaD). Cerebral hypoperfusion may initiate complex molecular and cellular inflammatory pathways that contribute to long-term cognitive impairment and memory loss. Here we used a bilateral common carotid artery stenosis (BCAS) mouse model of VaD to investigate its effect on the innate immune response—particularly the inflammasome signaling pathway. Comprehensive analyses revealed that chronic cerebral hypoperfusion induces a complex temporal expression and activation of inflammasome components and their downstream products (IL-1β and IL-18) in different brain regions, and promotes activation of apoptotic and pyroptotic cell death pathways. Polarized glial-cell activation, white-matter lesion formation and hippocampal neuronal loss also occurred in a spatiotemporal manner. Moreover, in AIM2 knockout mice we observed attenuated inflammasome-mediated production of proinflammatory cytokines, apoptosis, and pyroptosis, as well as resistance to chronic microglial activation, myelin breakdown, hippocampal neuronal loss, and behavioral and cognitive deficits following BCAS. Hence, we have demonstrated that activation of the AIM2 inflammasome substantially contributes to the pathophysiology of chronic cerebral hypoperfusion-induced brain injury and may therefore represent a promising therapeutic target for attenuating cognitive impairment in VaD.
UR - http://www.scopus.com/inward/record.url?scp=85097426053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097426053&partnerID=8YFLogxK
U2 - 10.1038/s41380-020-00971-5
DO - 10.1038/s41380-020-00971-5
M3 - Article
C2 - 33299135
AN - SCOPUS:85097426053
SN - 1359-4184
VL - 26
SP - 4544
EP - 4560
JO - Molecular Psychiatry
JF - Molecular Psychiatry
IS - 8
ER -